{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:38:53Z","timestamp":1790365133098,"version":"4.1.0"},"publisher-location":"Cham","reference-count":76,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319720760","type":"print"},{"value":"9783319720777","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-72077-7_10","type":"book-chapter","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T23:05:04Z","timestamp":1525388704000},"page":"207-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Engineering Antibodies for the Treatment of Infectious Diseases"],"prefix":"10.1007","author":[{"given":"Gaowei","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,17]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1084\/jem.20100995","volume":"207","author":"N Abboud","year":"2010","unstructured":"Abboud N, Chow S-K, Saylor C, Janda A, Ravetch JV, Scharff MD, Casadevall A (2010) A requirement for Fc\u03b3R in antibody-mediated bacterial toxin neutralization. J Exp Med 207:2395\u20132405. https:\/\/doi.org\/10.1084\/jem.20100995","journal-title":"J Exp Med"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"e100325","DOI":"10.1371\/journal.pone.0100325","volume":"9","author":"GJ Babcock","year":"2014","unstructured":"Babcock GJ, Iyer S, Smith HL, Wang Y, Rowley K, Ambrosino DM, Zamore PD, Pierce BG et al (2014) High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody. PLoS One 9:e100325. https:\/\/doi.org\/10.1371\/journal.pone.0100325","journal-title":"PLoS One"},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"10678","DOI":"10.1074\/jbc.272.16.10678","volume":"272","author":"M Baca","year":"1997","unstructured":"Baca M, Presta LG, O\u2019Connor SJ, Wells JA (1997) Antibody humanization using monovalent phage display. J Biol Chem 272:10678\u201310684","journal-title":"J Biol Chem"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1136\/ard.2005.049858","volume":"65","author":"GM Bartelds","year":"2006","unstructured":"Bartelds GM, Wolbink GJ, Stapel S, Aarden L, Lems WF, Dijkmans BAC, Nurmohamed MT (2006) High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 65:1249\u20131250. https:\/\/doi.org\/10.1136\/ard.2005.049858","journal-title":"Ann Rheum Dis"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1128\/AAC.01178-09","volume":"54","author":"JH Beigel","year":"2010","unstructured":"Beigel JH, Nordstrom JL, Pillemer SR, Roncal C, Goldwater DR, Li H, Holland PC, Johnson S et al (2010) Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob Agents Chemother 54:2431\u20132436. https:\/\/doi.org\/10.1128\/AAC.01178-09","journal-title":"Antimicrob Agents Chemother"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1073\/pnas.88.11.4723","volume":"88","author":"J Berg","year":"1991","unstructured":"Berg J, L\u00f6tscher E, Steimer KS, Capon DJ, Baenziger J, J\u00e4ck HM, Wabl M (1991) Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain. Proc Natl Acad Sci 88:4723\u20134727","journal-title":"Proc Natl Acad Sci"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.nbt.2011.03.018","volume":"28","author":"JD Berry","year":"2011","unstructured":"Berry JD, Gaudet RG (2011) Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. New Biotechnol 28:489\u2013501. https:\/\/doi.org\/10.1016\/j.nbt.2011.03.018","journal-title":"New Biotechnol"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-1-4419-5955-3_3","volume-title":"Development of antibody-based therapeutics","author":"RR Bhatt","year":"2012","unstructured":"Bhatt RR, Haurum JS, Davis CG (2012) Technologies for the generation of human antibodies. In: Tabrizi MA, Bornstein GG, Klakamp SL (eds) Development of antibody-based therapeutics. Springer, New York, pp 33\u201363. https:\/\/doi.org\/10.1007\/978-1-4419-5955-3_3"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0190-9622(85)70182-X","volume":"13","author":"L Bielory","year":"1985","unstructured":"Bielory L, Yancey KB, Young NS, Frank MM, Lawley TJ (1985) Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin. J Am Acad Dermatol 13:411\u2013417. https:\/\/doi.org\/10.1016\/S0190-9622(85)70182-X","journal-title":"J Am Acad Dermatol"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/1756283X12454590","volume":"6","author":"J Bien","year":"2013","unstructured":"Bien J, Palagani V, Bozko P (2013) The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Ther Adv Gastroenterol 6:53\u201368. https:\/\/doi.org\/10.1177\/1756283X12454590","journal-title":"Ther Adv Gastroenterol"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/protein\/gzl057","volume":"20","author":"DR Bowley","year":"2007","unstructured":"Bowley DR, Labrijn AF, Zwick MB, Burton DR (2007) Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. Protein Eng Des Sel PEDS 20:81\u201390. https:\/\/doi.org\/10.1093\/protein\/gzl057","journal-title":"Protein Eng Des Sel PEDS"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0167-5699(96)10025-6","volume":"17","author":"M Br\u00fcggemann","year":"1996","unstructured":"Br\u00fcggemann M, Neuberger MS (1996) Strategies for expressing human antibody repertoires in transgenic mice. Immunol Today 17:391\u2013397. https:\/\/doi.org\/10.1016\/0167-5699(96)10025-6","journal-title":"Immunol Today"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1128\/AAC.38.8.1695","volume":"38","author":"A Casadevall","year":"1994","unstructured":"Casadevall A, Scharff MD (1994) Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 38:1695\u20131702","journal-title":"Antimicrob Agents Chemother"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/clinids\/21.1.150","volume":"21","author":"A Casadevall","year":"1995","unstructured":"Casadevall A, Scharff MD (1995) Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis Off Publ Infect Dis Soc Am 21:150\u2013161","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrmicro974","volume":"2","author":"A Casadevall","year":"2004","unstructured":"Casadevall A, Dadachova E, Pirofski L (2004) Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2:695\u2013703. https:\/\/doi.org\/10.1038\/nrmicro974","journal-title":"Nat Rev Microbiol"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/ajt.12083","volume":"13","author":"RT Chung","year":"2013","unstructured":"Chung RT, Gordon FD, Curry MP, Schiano TD, Emre S, Corey K, Markmann J et\u00a0al (2013) Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 13:1047\u20131054. https:\/\/doi.org\/10.1111\/ajt.12083","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1126\/science.257.5073.1050","volume":"257","author":"ML Cohen","year":"1992","unstructured":"Cohen ML (1992) Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257:1050\u20131055","journal-title":"Science"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.virol.2006.09.029","volume":"361","author":"M Coughlin","year":"2007","unstructured":"Coughlin M, Lou G, Martinez O, Masterman SK, Olsen OA, Moksa AA, Farzan M et al (2007) Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 361:93\u2013102. https:\/\/doi.org\/10.1016\/j.virol.2006.09.029","journal-title":"Virology"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/nbt1260","volume":"24","author":"KM Cox","year":"2006","unstructured":"Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, Black A et al (2006) Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 24:1591\u20131597. https:\/\/doi.org\/10.1038\/nbt1260","journal-title":"Nat Biotechnol"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7326\/0003-4819-121-1-199407010-00011","volume":"121","author":"AS Cross","year":"1994","unstructured":"Cross AS (1994) Antiendotoxin antibodies: a dead end? Ann Intern Med 121:58\u201360","journal-title":"Ann Intern Med"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ymeth.2005.01.005","volume":"36","author":"WF Dall\u2019Acqua","year":"2005","unstructured":"Dall\u2019Acqua WF, Damschroder MM, Zhang J, Woods RM, Widjaja L, Yu J, Wu H (2005) Antibody humanization by framework shuffling. Methods 36:43\u201360. https:\/\/doi.org\/10.1016\/j.ymeth.2005.01.005","journal-title":"Methods"},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.molimm.2006.12.019","volume":"44","author":"MM Damschroder","year":"2007","unstructured":"Damschroder MM, Widjaja L, Gill PS, Krasnoperov V, Jiang W, Dall\u2019Acqua WF, Wu H (2007) Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties. Mol Immunol 44:3049\u20133060. https:\/\/doi.org\/10.1016\/j.molimm.2006.12.019","journal-title":"Mol Immunol"},{"key":"10_CR23","first-page":"5521","volume":"9","author":"R Pascalis De","year":"2003","unstructured":"De Pascalis R, Gonzales NR, Padlan EA, Schuck P, Batra SK, Schlom J, Kashmiri SVS (2003) In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants. Clin Cancer Res Off J Am Assoc Cancer Res 9:5521\u20135531","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-1-59745-471-1_16","volume-title":"Gene knockout protocols, methods in molecular biology","author":"T DeChiara","year":"2009","unstructured":"DeChiara T, Poueymirou W, Auerbach W, Frendewey D, Yancopoulos G, Valenzuela D (2009) VelociMouse: fully ES cell-derived F0-generation mice obtained from the injection of ES cells into eight-cell-stage embryos. In: Wurst W, K\u00fchn R (eds) Gene knockout protocols, methods in molecular biology. Humana Press, New York, pp 311\u2013324. https:\/\/doi.org\/10.1007\/978-1-59745-471-1_16"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nbt.2492","volume":"31","author":"BJ DeKosky","year":"2013","unstructured":"DeKosky BJ, Ippolito GC, Deschner RP, Lavinder JJ, Wine Y, Rawlings BM, Varadarajan N et al (2013) High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat Biotechnol 31:166\u2013169. https:\/\/doi.org\/10.1038\/nbt.2492","journal-title":"Nat Biotechnol"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1086\/515184","volume":"28","author":"B Derkx","year":"1999","unstructured":"Derkx B, Wittes J, McCloskey R (1999) Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis Off Publ Infect Dis Soc Am 28:770\u2013777. https:\/\/doi.org\/10.1086\/515184","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-014-0099-8","volume":"8","author":"G Fan","year":"2015","unstructured":"Fan G, Wang Z, Hao M, Li J (2015) Bispecific antibodies and their applications. J Hematol Oncol 8:1\u201314. https:\/\/doi.org\/10.1186\/s13045-015-0227-0","journal-title":"J Hematol Oncol"},{"key":"10_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/jac\/43.4.459","volume":"43","author":"IM Gould","year":"1999","unstructured":"Gould IM (1999) A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 43:459\u2013465","journal-title":"J Antimicrob Chemother"},{"key":"10_CR29","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jama.1991.03470080067031","volume":"266","author":"RL Greenman","year":"1991","unstructured":"Greenman RL, Schein RMH, Martin MA, Wenzel RP, Maclntyre NR, Emmanuel G, Chmel H et al (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097\u20131102. https:\/\/doi.org\/10.1001\/jama.1991.03470080067031","journal-title":"JAMA"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1542\/peds.102.3.531","volume":"102","author":"Group*, T.Im.-R.S","year":"1998","unstructured":"Group*, T.Im.-R.S (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531\u2013537. https:\/\/doi.org\/10.1542\/peds.102.3.531","journal-title":"Pediatrics"},{"key":"10_CR31","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/infdis\/jiv042","volume":"211","author":"A Gutfraind","year":"2015","unstructured":"Gutfraind A, Meyers LA (2015) Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia. J Infect Dis 211:1262\u20131267. https:\/\/doi.org\/10.1093\/infdis\/jiv042","journal-title":"J Infect Dis"},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1126\/science.2531466","volume":"246","author":"WD Huse","year":"1989","unstructured":"Huse WD, Sastry L, Iverson SA, Kang AS, Alting-Mees M, Burton DR, Benkovic SJ et al (1989) Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246:1275\u20131281","journal-title":"Science"},{"key":"10_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.tibtech.2007.05.001","volume":"25","author":"M Jain","year":"2007","unstructured":"Jain M, Kamal N, Batra SK (2007) Engineering antibodies for clinical applications. Trends Biotechnol 25:307\u2013316. https:\/\/doi.org\/10.1016\/j.tibtech.2007.05.001","journal-title":"Trends Biotechnol"},{"key":"10_CR34","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/nbt1337","volume":"25","author":"A Jakobovits","year":"2007","unstructured":"Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25:1134\u20131143. https:\/\/doi.org\/10.1038\/nbt1337","journal-title":"Nat Biotechnol"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1517\/14712598.7.9.1401","volume":"7","author":"R Jefferis","year":"2007","unstructured":"Jefferis R (2007) Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 7:1401\u20131413. https:\/\/doi.org\/10.1517\/14712598.7.9.1401","journal-title":"Expert Opin Biol Ther"},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1099\/mic.0.040618-0","volume":"156","author":"C Jernberg","year":"2010","unstructured":"Jernberg C, L\u00f6fmark S, Edlund C, Jansson JK (2010) Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiol Read Engl 156:3216\u20133223. https:\/\/doi.org\/10.1099\/mic.0.040618-0","journal-title":"Microbiol Read Engl"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/nm.1966","volume":"15","author":"A Jin","year":"2009","unstructured":"Jin A, Ozawa T, Tajiri K, Obata T, Kondo S, Kinoshita K, Kadowaki S et al (2009) A rapid and efficient single-cell manipulation method for screening antigen-specific antibody\u2013secreting cells from human peripheral blood. Nat Med 15:1088\u20131092. https:\/\/doi.org\/10.1038\/nm.1966","journal-title":"Nat Med"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ymeth.2005.01.003","volume":"36","author":"SVS Kashmiri","year":"2005","unstructured":"Kashmiri SVS, De Pascalis R, Gonzales NR, Schlom J (2005) SDR grafting\u00a0\u2013 a new approach to antibody humanization. Methods 36:25\u201334. https:\/\/doi.org\/10.1016\/j.ymeth.2005.01.003","journal-title":"Methods"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrd4525","volume":"14","author":"K Kingwell","year":"2015","unstructured":"Kingwell K (2015) Infectious diseases: two-hit antibody tackles bacteria. Nat Rev Drug Discov 14:15\u201315. https:\/\/doi.org\/10.1038\/nrd4525","journal-title":"Nat Rev Drug Discov"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495\u2013497. https:\/\/doi.org\/10.1038\/256495a0","journal-title":"Nature"},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","volume":"22","author":"RE Kontermann","year":"2011","unstructured":"Kontermann RE (2011) Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 22:868\u2013876. https:\/\/doi.org\/10.1016\/j.copbio.2011.06.012","journal-title":"Curr Opin Biotechnol"},{"key":"10_CR42","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nbt.1521","volume":"27","author":"Y Kuroiwa","year":"2009","unstructured":"Kuroiwa Y, Kasinathan P, Choi YJ, Naeem R, Tomizuka K, Sullivan EJ, Knott JG et al (2009) Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 27:767\u2013771. https:\/\/doi.org\/10.1038\/nbt.1553","journal-title":"Nat Biotechnol"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.molimm.2006.09.029","volume":"44","author":"GA Lazar","year":"2007","unstructured":"Lazar GA, Desjarlais JR, Jacinto J, Karki S, Hammond PW (2007) A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol 44:1986\u20131998. https:\/\/doi.org\/10.1016\/j.molimm.2006.09.029","journal-title":"Mol Immunol"},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nbt1178","volume":"24","author":"H Li","year":"2006","unstructured":"Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, Bobrowicz P, Choi B-K et al (2006) Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 24:210\u2013215. https:\/\/doi.org\/10.1038\/nbt1178","journal-title":"Nat Biotechnol"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1056\/NEJMoa0907635","volume":"362","author":"I Lowy","year":"2010","unstructured":"Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G et al (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197\u2013205. https:\/\/doi.org\/10.1056\/NEJMoa0907635","journal-title":"N Engl J Med"},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/nbt1363","volume":"25","author":"WA Marasco","year":"2007","unstructured":"Marasco WA, Sui J (2007) The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25:1421\u20131434. https:\/\/doi.org\/10.1038\/nbt1363","journal-title":"Nat Biotechnol"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nm1240","volume":"11","author":"T Oliphant","year":"2005","unstructured":"Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S et al (2005) Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11:522\u2013530. https:\/\/doi.org\/10.1038\/nm1240","journal-title":"Nat Med"},{"key":"10_CR48","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/S0161-5890(01)00027-X","volume":"37","author":"SS Park","year":"2000","unstructured":"Park SS, Ryu CJ, Kang YJ, Kashmiri SVS, Hong HJ (2000) Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens. Mol Immunol 37:1123\u20131130. https:\/\/doi.org\/10.1016\/S0161-5890(01)00027-X","journal-title":"Mol Immunol"},{"key":"10_CR49","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.coi.2008.06.012","volume":"20","author":"LG Presta","year":"2008","unstructured":"Presta LG (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20:460\u2013470. https:\/\/doi.org\/10.1016\/j.coi.2008.06.012","journal-title":"Curr Opin Immunol"},{"key":"10_CR50","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/nbt.1673","volume":"28","author":"ST Reddy","year":"2010","unstructured":"Reddy ST, Ge X, Miklos AE, Hughes RA, Kang SH, Hoi KH, Chrysostomou C et al (2010) Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat Biotechnol 28:965\u2013969. https:\/\/doi.org\/10.1038\/nbt.1673","journal-title":"Nat Biotechnol"},{"key":"10_CR51","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/nbt1207-1369","volume":"25","author":"JG Salfeld","year":"2007","unstructured":"Salfeld JG (2007) Isotype selection in antibody engineering. Nat Biotechnol 25:1369\u20131372. https:\/\/doi.org\/10.1038\/nbt1207-1369","journal-title":"Nat Biotechnol"},{"key":"10_CR52","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1006\/jmbi.1996.0598","volume":"263","author":"R Schier","year":"1996","unstructured":"Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS et al (1996) Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 263:551\u2013567. https:\/\/doi.org\/10.1006\/jmbi.1996.0598","journal-title":"J Mol Biol"},{"key":"10_CR53","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/protein\/gzh098","volume":"17","author":"M Schlapschy","year":"2004","unstructured":"Schlapschy M, Gruber H, Gresch O, Sch\u00e4fer C, Renner C, Pfreundschuh M, Skerra A (2004) Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin\u2019s lymphoma using an in vitro evolution approach. Protein Eng Des Sel PEDS 17:847\u2013860. https:\/\/doi.org\/10.1093\/protein\/gzh098","journal-title":"Protein Eng Des Sel PEDS"},{"key":"10_CR54","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","volume":"277","author":"RL Shields","year":"2002","unstructured":"Shields RL, Lai J, Keck R, O\u2019Connell LY, Hong K, Meng YG, Weikert SHA et al (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc\u03b3RIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733\u201326740. https:\/\/doi.org\/10.1074\/jbc.M202069200","journal-title":"J Biol Chem"},{"key":"10_CR55","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1182\/blood-2008-05-158824","volume":"113","author":"Z Stamataki","year":"2009","unstructured":"Stamataki Z, Shannon-Lowe C, Shaw J, Mutimer D, Rickinson AB, Gordon J, Adams DH et al (2009) Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood 113:585\u2013593. https:\/\/doi.org\/10.1182\/blood-2008-05-158824","journal-title":"Blood"},{"key":"10_CR56","doi-asserted-by":"publisher","first-page":"8882","DOI":"10.1158\/0008-5472.CAN-07-0696","volume":"67","author":"JB Stavenhagen","year":"2007","unstructured":"Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L et al (2007) Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fc\u03b3 receptors. Cancer Res 67:8882\u20138890. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0696","journal-title":"Cancer Res"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.immuni.2007.11.018","volume":"28","author":"Z-YJ Sun","year":"2008","unstructured":"Sun Z-YJ, Oh KJ, Kim M, Yu J, Brusic V, Song L, Qiao Z et al (2008) HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28:52\u201363. https:\/\/doi.org\/10.1016\/j.immuni.2007.11.018","journal-title":"Immunity"},{"key":"10_CR58","volume-title":"Development of antibody-based therapeutics","year":"2012","unstructured":"Tabrizi MA, Bornstein GG, Klakamp SL (eds) (2012) Development of antibody-based therapeutics. Springer, New York"},{"issue":"169","key":"10_CR59","first-page":"1119","volume":"1950","author":"P Tan","year":"2002","unstructured":"Tan P, Mitchell DA, Buss TN, Holmes MA, Anasetti C, Foote J (2002) \u201cSuperhumanized\u201d antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol Baltim Md 1950(169):1119\u20131125","journal-title":"J Immunol Baltim Md"},{"key":"10_CR60","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.4049\/jimmunol.159.8.4035","volume":"159","author":"RP Taylor","year":"1997","unstructured":"Taylor RP, Martin EN, Reinagel ML, Nardin A, Craig M, Choice Q, Schlimgen R et al (1997) Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model. J Immunol 159:4035\u20134044","journal-title":"J Immunol"},{"key":"10_CR61","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1073\/pnas.82.6.1790","volume":"82","author":"NN Teng","year":"1985","unstructured":"Teng NN, Kaplan HS, Hebert JM, Moore C, Douglas H, Wunderlich A, Braude AI (1985) Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci U S A 82:1790\u20131794","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003942","volume":"3","author":"M Throsby","year":"2008","unstructured":"Throsby M, van den BE, Jongeneelen M, Poon LLM, Alard P, Cornelissen L, Bakker A, Cox F, van DE, Guan Y et al (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3:e3942. https:\/\/doi.org\/10.1371\/journal.pone.0003942","journal-title":"PLoS One"},{"key":"10_CR63","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jim.2009.08.009","volume":"350","author":"T Tiller","year":"2009","unstructured":"Tiller T, Busse CE, Wardemann H (2009) Cloning and expression of murine Ig genes from single B cells. J Immunol Methods 350:183\u2013193. https:\/\/doi.org\/10.1016\/j.jim.2009.08.009","journal-title":"J Immunol Methods"},{"key":"10_CR64","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nm1080","volume":"10","author":"E Traggiai","year":"2004","unstructured":"Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR et al (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871\u2013875. https:\/\/doi.org\/10.1038\/nm1080","journal-title":"Nat Med"},{"key":"10_CR65","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.4049\/jimmunol.137.11.3566","volume":"137","author":"JS Zee Van Der","year":"1986","unstructured":"Van Der Zee JS, Van Swieten P, Aalberse RC (1986) Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol 137:3566\u20133571","journal-title":"J Immunol"},{"key":"10_CR66","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1128\/AAC.02643-14","volume":"58","author":"P Warrener","year":"2014","unstructured":"Warrener P, Varkey R, Bonnell JC, DiGiandomenico A, Camara M, Cook K, Peng L et al (2014) A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. Antimicrob Agents Chemother 58:4384\u20134391. https:\/\/doi.org\/10.1128\/AAC.02643-14","journal-title":"Antimicrob Agents Chemother"},{"key":"10_CR67","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1542\/peds.2010-3081","volume":"128","author":"LE Weisman","year":"2011","unstructured":"Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, Brozanski BS et al (2011) A randomized study of a monoclonal antibody (Pagibaximab) to prevent staphylococcal sepsis. Pediatrics 128:271\u2013279. https:\/\/doi.org\/10.1542\/peds.2010-3081","journal-title":"Pediatrics"},{"key":"10_CR68","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/eji.200425936","volume":"35","author":"M Wiesner","year":"2005","unstructured":"Wiesner M, Zentz C, Hammer MH, Cobbold M, Kern F, Kolb H-J, Hammerschmidt W et al (2005) Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines. Eur J Immunol 35:2110\u20132121. https:\/\/doi.org\/10.1002\/eji.200425936","journal-title":"Eur J Immunol"},{"key":"10_CR69","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1073\/pnas.1213737110","volume":"110","author":"Y Wine","year":"2013","unstructured":"Wine Y, Boutz DR, Lavinder JJ, Miklos AE, Hughes RA, Hoi KH, Jung ST et al (2013) Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response. Proc Natl Acad Sci 110:2993\u20132998. https:\/\/doi.org\/10.1073\/pnas.1213737110","journal-title":"Proc Natl Acad Sci"},{"key":"10_CR70","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1423-0410.1994.tb01270.x","volume":"67","author":"YHJ Yang\u2020","year":"1994","unstructured":"Yang\u2020 YHJ, Ngo C, Yeh IN, Uemura Y (1994) Antibody Fc functional activity of intravenous immunoglobulin preparations treated with solvent-detergent for virus inactivation. Vox Sang 67:337\u2013344. https:\/\/doi.org\/10.1111\/j.1423-0410.1994.tb01270.x","journal-title":"Vox Sang"},{"key":"10_CR71","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1006\/jmbi.1995.0626","volume":"254","author":"WP Yang","year":"1995","unstructured":"Yang WP, Green K, Pinz-Sweeney S, Briones AT, Burton DR, Barbas CF (1995) CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 254:392\u2013403","journal-title":"J Mol Biol"},{"key":"10_CR72","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.molimm.2013.11.011","volume":"58","author":"J Yang","year":"2014","unstructured":"Yang J, Goetze AM, Flynn GC (2014) Assessment of naturally occurring covalent and total dimer levels in human IgG1 and IgG2. Mol Immunol 58:108\u2013115. https:\/\/doi.org\/10.1016\/j.molimm.2013.11.011","journal-title":"Mol Immunol"},{"key":"10_CR73","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ab.2015.06.014","volume":"484","author":"X Yang","year":"2015","unstructured":"Yang X, Zhang Y, Wang F, Wang LJ, Richardson D, Shameem M, Ambrogelly A (2015) Analysis and purification of IgG4 bispecific antibodies by a mixed-mode chromatography. Anal Biochem 484:173\u2013179. https:\/\/doi.org\/10.1016\/j.ab.2015.06.014","journal-title":"Anal Biochem"},{"issue":"170","key":"10_CR74","first-page":"3134","volume":"1950","author":"EM Yoo","year":"2003","unstructured":"Yoo EM, Wims LA, Chan LA, Morrison SL (2003) Human IgG2 can form covalent dimers. J Immunol Baltim Md 1950(170):3134\u20133138","journal-title":"J Immunol Baltim Md"},{"key":"10_CR75","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, Lazar GA et al (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28:157\u2013159. https:\/\/doi.org\/10.1038\/nbt.1601","journal-title":"Nat Biotechnol"},{"key":"10_CR76","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJM199102143240701","volume":"324","author":"EJ Ziegler","year":"1991","unstructured":"Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324:429\u2013436. https:\/\/doi.org\/10.1056\/NEJM199102143240701","journal-title":"N Engl J Med"}],"container-title":["Advances in Experimental Medicine and Biology","Recombinant Antibodies for Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-72077-7_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T12:12:33Z","timestamp":1693656753000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-72077-7_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319720760","9783319720777"],"references-count":76,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-72077-7_10","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"17 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}